On May 22, 2008, the American Diabetes Association (“ADA”), in conjunction with the 68th Scientific Session, provided registered attendees with copies of abstracts to be presented at the annual ADA Meeting in San Francisco, June 6-10, 2008. Included in the Scientific Session Abstract Book is an abstract relating to our investigational product candidate Qnexa(TM) for the treatment of Type 2 Diabetes. The full text of the ADA abstract materials concerning the foregoing is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Text of ADA Abstract titled “[390-OR] Effect of VI-0521 (Phentermine and Topiramate) in Type 2 Diabetes.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VIVUS, INC. |
|
|
|
|
|
/s/ Lee B. Perry |
|
|
Lee B. Perry |
|
|
Vice President and Chief Accounting Officer |
Date: May 22, 2008
EXHIBIT INDEX
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Text of ADA Abstract titled “[390-OR] Effect of VI-0521 (Phentermine and Topiramate) in Type 2 Diabetes.” |